8-K: Arbutus Biopharma Details LNP Patent Lawsuits

Arbutus Biopharma presented an update on its ongoing patent infringement lawsuits against Moderna, Pfizer, and BioNTech regarding their COVID-19 vaccines' use of patented lipid nanoparticle technology.

Summary

• Arbutus Biopharma, through its joint venture Genevant, is pursuing patent infringement lawsuits against Moderna, Pfizer, and BioNTech for their use of patented lipid nanoparticle (LNP) technology in their COVID-19 vaccines (SPIKEVAX and COMIRNATY).
• Global COVID-19 vaccine sales by Moderna and Pfizer/BioNTech have totaled approximately $145 billion since launch as of September 30, 2025.
• Markman rulings (claim construction) in both the US Moderna and US Pfizer/BioNTech cases have been issued and are viewed by Genevant as generally favorable.
• A jury trial in the US Moderna litigation is scheduled to commence in March 2026, expected to last approximately two weeks.
• Initial court hearings and rulings in the ex-US Moderna litigation are anticipated in 2026, with further hearings in UPC, Japan, Switzerland, and Canada expected in 2027.
• Litigation against Pfizer/BioNTech in the US is currently in the fact discovery phase, with future court scheduling awaited.
• The company is seeking appropriate compensation for the unauthorized use of its patented technology and is not seeking an injunction to impede vaccine sales.

Sentiment

Score: 7

Explanation: The company expresses strong confidence in its patent infringement claims against Moderna, Pfizer, and BioNTech, citing favorable Markman rulings and unsuccessful challenges to its patents. The potential recovery from over $145 billion in vaccine sales is substantial. However, the litigation is ongoing, complex, and subject to significant uncertainties, including potential appeals and the US DOJ's involvement.

Positives

• Markman rulings (claim construction) in both the US Moderna and US Pfizer/BioNTech cases are viewed by Genevant as generally favorable, strengthening the company's position.
• Moderna's previous Inter Partes Review (IPR) challenges to two of the particle composition patents (8,058,069 and 8,492,359) were largely unsuccessful, indicating the robustness of the patents.
• The potential damages pool is substantial, with global COVID-19 vaccine sales by Moderna and Pfizer/BioNTech exceeding $145 billion.
• Publicly available evidence, including BioNTech's prior license agreement for Genevant LNP technology for non-COVID targets and FDA EUA filings, supports the infringement claims against Pfizer/BioNTech.

Negatives

• Litigation is inherently subject to significant business, economic, competitive, market, and social uncertainties and contingencies, meaning actual results could differ materially from expectations.
• The US Department of Justice filed a Statement of Interest in support of Moderna in early 2023, which could introduce additional complexities or risks in the US Moderna case.
• The company disclaims any obligation to revise or update forward-looking statements, highlighting the inherent uncertainties and the speculative nature of litigation outcomes.

Risks

• Uncertainties associated with litigation generally and patent litigation specifically.
• Economic and market conditions may worsen, potentially impacting the value of any awarded damages or the ability to collect.
• Market shifts may require a change in strategic focus, diverting resources or attention.
• Risks related to the sufficiency of the Company's cash resources for its foreseeable and unforeseeable operating expenses and capital expenditures, especially given the costs of prolonged litigation.
• Actual results, performance, or achievements could be materially different from any future results, performance, or achievements expressed or implied by forward-looking statements.

Future Outlook

The company anticipates significant legal milestones in the near future, including rulings on summary judgment and Daubert motions in the US Moderna case before a jury trial scheduled for March 2026. Initial international hearings for ex-US Moderna litigation are expected in 2026, with further hearings in specific jurisdictions like UPC, Japan, Switzerland, and Canada projected for 2027. Any jury verdict is expected to be appealed, potentially extending the litigation process by an additional 18-24 months. Court scheduling for the Pfizer/BioNTech litigation is still pending.

Management Comments

• "We believe that both the Moderna COVID-19 vaccine (SPIKEVAX) and Pfizer/BioNTech's COVID-19 vaccine (COMIRNATY) infringe multiple Genevant/Arbutus LNP patents."
• "Markman rulings (claim construction) have been issued in both US cases – viewed by Genevant generally to be favorable."
• "Genevant and Arbutus did not seek an injunction or otherwise to impede the sale, manufacture, or distribution of Moderna's COVID-19 vaccine, given the unprecedented global emergency."
• "We recognize the important work of Moderna that helped lead to a lifesaving vaccine in record time. That success was built on, and made possible by, the substantial advances and contributions of Arbutus and Genevant scientists, which Moderna utilized extensively well before COVID-19."
• "The filing of this lawsuit was necessary because Moderna did not pursue and obtain a license to Genevant's LNP technology for COVID-19."

Industry Context

The filing highlights the foundational importance of lipid nanoparticle (LNP) technology in the development and commercial success of mRNA-based vaccines, particularly for COVID-19. Arbutus/Genevant's historical role as a pioneer in LNP technology, including its involvement in Alnylam's FDA-approved RNA product Onpattro, underscores its significant intellectual property position. The substantial revenues generated by Moderna and Pfizer/BioNTech's vaccines (over $145 billion) illustrate the immense commercial value of this technology and the high stakes involved in intellectual property disputes within the rapidly evolving biopharmaceutical sector.

Comparison to Industry Standards

• Arbutus's LNP technology, through its license to Alnylam, was the first LNP technology to be part of an FDA-approved RNA product (Onpattro), establishing an industry-leading benchmark for nucleic acid delivery capabilities.
• BioNTech's 2018 license agreement with Genevant for LNP technology for specific cancer and rare liver disease targets described Genevant's platform as the 'best lipid nanoparticle technology,' indicating its superior standing in the industry.
• The over $145 billion in global COVID-19 vaccine sales by Moderna and Pfizer/BioNTech represents an unprecedented commercial success for mRNA vaccines, setting a high bar for the market value of LNP-enabled therapeutics and the potential damages in this litigation.

Legal Proceedings

• Ongoing patent infringement lawsuits against Moderna Therapeutics, Inc., Pfizer Inc., and BioNTech SE for their use of patented lipid nanoparticle (LNP) technology in their COVID-19 vaccines.
• US Moderna litigation: Filed in the US District Court for the District of Delaware, with a jury trial scheduled for March 2026.
• Ex-US Moderna litigation: International proceedings initiated, with initial court hearings and rulings expected in 2026, and further hearings in UPC, Japan, Switzerland, and Canada expected in 2027.
• US Pfizer/BioNTech litigation: Complaint filed in the US District Court for the District of New Jersey, currently undergoing fact discovery with court scheduling awaited.
• Moderna previously sought to invalidate two particle composition patents (8,058,069 and 8,492,359) through IPR challenges but was largely unsuccessful.
• The US Department of Justice filed a Statement of Interest in support of Moderna in early 2023 in the US Moderna case.

Stakeholder Impact

• Shareholders: Potential for significant financial recovery if the litigation is successful, which could substantially increase shareholder value. However, the inherent costs, duration, and uncertainties of complex patent litigation pose considerable risks to investment.
• Employees: A successful outcome could lead to increased resources for research and development, potentially benefiting employees through enhanced opportunities and job security.
• Customers (of Moderna/Pfizer/BioNTech): No direct impact on vaccine availability or pricing, as Arbutus/Genevant are not seeking an injunction to halt sales, focusing solely on compensation.
• Industry Competitors: The outcome of these high-profile cases could set important precedents for intellectual property enforcement and licensing practices within the biopharmaceutical industry, particularly concerning foundational platform technologies like LNPs.

Next Steps

• Judge to rule on summary judgment motions, including the decision on Section 1498, before the jury trial in March 2026 (US Moderna case).
• Judge to rule on Daubert motions, which could narrow the expert testimony allowed to be presented on both sides or impact presentations on damages, infringement, willful infringement, and invalidity (US Moderna case).
• A jury trial is currently scheduled to start on March 9, 2026, in the U.S. District Court of Delaware for the US Moderna case, with jury selection and presentations over approximately two weeks.
• Jury deliberation and issuance of a verdict in the US Moderna case.
• Post-trial motions entertained by the trial court in the period after the trial (US Moderna case).
• Any jury verdict is expected to be appealed, which could take an additional 18-24 months.
• If the jury rules favorably for Genevant/Arbutus, Moderna would likely need to obtain a bond or post cash collateral with the court within 30 days to obtain a stay of execution of judgment pending appeal.
• Initial hearings expected in 2026 for ex-US Moderna litigation.
• Initial hearings expected in 2027 for ex-US Moderna litigation in UPC, Japan, Switzerland, and Canada.
• Awaiting court scheduling on future deadlines for the Pfizer/BioNTech litigation.

Key Dates

Recommendation

The company has presented a strong case for patent infringement against major pharmaceutical companies, with favorable initial rulings on claim construction and a clear path to trial. The potential damages are substantial, given the over $145 billion in vaccine sales. However, patent litigation is inherently long, expensive, and uncertain, with appeals likely regardless of the initial verdict. The involvement of the US DOJ in the Moderna case adds a layer of complexity. Therefore, a "hold" recommendation is appropriate, allowing investors to monitor the progression of these high-stakes legal battles before making further investment decisions.

Keywords

LNP, lipid nanoparticle, patent infringement, Moderna, Pfizer, BioNTech, COVID-19 vaccine, litigation, intellectual property, biopharma, Arbutus, Genevant